August is World Alzheimer’s Disease Month, and while awareness continues to grow, so does the urgency.
Alzheimer’s affects more than 7 million Americans today and is projected to surpass 13 million by 2050. Global care costs are already spiraling past $384 billion per year, and yet 70% of Alzheimer’s drug trials fail in Phase III. The gap between science and clinical impact is wide—but narrowing fast.
What’s changing?
A wave of startups is shifting focus from treatment alone to early detection, remote support, and scalable care infrastructure. And that shift is creating real opportunities for founders, investors, and health systems alike.
The 2025 Alzheimer’s HealthTech Value Chain
To succeed in this space, a product must do more than “detect Alzheimer’s.” It must deliver ROI across one or more of these six value-chain stages:
-
Capture – Early, reliable biomarkers from blood, retina, or speech
-
Interpret – AI + imaging that turn biomarkers into decision-making tools
-
Monitor & Engage – Long-term care and home-based disease management
-
Treat & Intervene – Non-drug interventions that improve outcomes
-
Discover – Platforms driving new therapeutics
-
Scale – Compliance, payer alignment, and real-world usability
Let’s break it down by category:
1. Biomarker Diagnostics
Startups in this space are developing blood, saliva, CSF, and retina-based tests to detect Alzheimer’s before symptoms begin—often at primary care level or even home settings.
Leading startups:
-
C2N Diagnostics – PrecivityAD™ and PrecivityAD2™ blood tests show over 90% accuracy for early AD diagnosis
-
ALZPath – CLIA-certified pTau217 immunoassay for clinical and trial use
-
Diadem – AlzoSure® Predict forecasts dementia progression from MCI
-
Pre Diagnostics – Immune biomarker-based early detection platform
-
Araclon Biotech – ABtest® for blood and CSF amyloid analysis
-
RetiSpec, Optina Diagnostics, NeuroVision Imaging, Cognoptix – Retinal image analysis for cerebral amyloid burden
-
Quanterix – Simoa® assays for ultra-sensitive plasma biomarker detection
Why it matters:
Detecting Alzheimer’s at the biomarker stage improves clinical outcomes and reduces per-patient care costs by up to $10,000/year when intervention starts early.
2. AI Imaging & MRI Analytics
These startups use AI to quantify brain atrophy, white matter lesions, hippocampal volumes, and ARIA for therapy response.
Startups to watch:
-
Qynapse, Cortechs.ai, icometrix, Combinostics, IXICO, Quantib, Brainreader, Quibim, Pixyl, Subtle Medical
Why it matters:
Radiology is a bottleneck in dementia diagnosis. These tools improve scan efficiency, triage accuracy, and throughput—translating into faster time-to-diagnosis and hospital cost reductions.
3. Digital Cognitive & Speech Assessment
From voice biomarkers to mobile assessments, these startups offer scalable, validated tools for trials, clinics, and at-home use.
Startups leading the way:
-
Linus Health, Altoida, Cogstate, BrainCheck, Neurotrack, Cognetivity, Cambridge Cognition, Winterlight Labs, Aural Analytics, Canary Speech, ki:elements, Sonde Health, Cumulus Neuroscience, Cogniciti (Baycrest)
Why it matters:
Traditional cognitive assessments take time and clinician involvement. These digital tools cut screening time by up to 80%, expanding access and saving clinicians up to 2 hours/week.
4. Remote Monitoring & Care
These platforms move Alzheimer’s care into the home, detecting risk early, improving patient safety, and supporting caregivers.
Key platforms:
-
CarePredict, SafelyYou, MapHabit, MyndYou, Rendever, ElliQ, GrandPad, Memory Lane Games, Tover, Neuroglee Health, Ceras Health
Why it matters:
Fall-related injuries and missed health signals are major cost drivers. Remote monitoring can reduce ER visits by 22% and improve medication adherence by 30% in memory care settings.
5. Digital Therapeutics & Neuromodulation
These startups provide non-pharmacologic, home-based interventions to slow progression or improve cognitive function.
Innovators in this space:
-
Cognito Therapeutics – Spectris™ 40 Hz light/sound DTx; FDA Breakthrough Device
-
Vielight, NeuroEM Therapeutics, Soterix Medical, Posit Science (BrainHQ), Transcranial Pulse Stimulation, Personalized rTMS, Gamma tACS programs
Why it matters:
These therapies are low-risk, non-invasive, and in some cases, more accessible than drugs—ideal for aging populations and underserved care settings.
6. Drug Discovery & Biotech
These companies are pushing forward next-gen anti-amyloid, anti-tau, neuroinflammation, and gene-targeted therapies.
Companies leading this shift:
-
Alzheon, Cognition Therapeutics, Annovis Bio, AC Immune, Alector, Vaxxinity, INmune Bio, Alzinova, TauRx, Annexon
Why it matters:
Alzheimer’s drug development is high risk but high reward. New mechanisms and precision targeting are attracting pharma partnerships and de-risking clinical development.
Why It All Adds Up to Opportunity
Healthcare providers, payers, and families are actively seeking:
-
Early detection that saves cost
-
Non-invasive interventions with proof
-
Scalable care that lightens the burden on systems and caregivers
Yet many startups fail to connect the clinical value to ROI, integration, or adoption.
How GrowthVybz Helps Alzheimer’s Innovators Succeed
Whether you’re pre-launch or scaling into providers or pharma, we help Alzheimer’s-focused startups:
-
Map unmet needs & market dynamics across the value chain
-
Build lead generation funnels with clinics, CROs, and memory care networks
-
Create pitch decks and grant content aligned to clinical and caregiver value
-
Design go-to-market strategies that convert pilots into partnerships
Stat-Driven CTA:
A 10% adoption of blood biomarker testing (e.g. C2N’s PrecivityAD2) could save $1B+ annually in delayed diagnosis and misallocated care. That’s not just impact—it’s your commercial case.
Disclaimer:
All company names, logos, and trademarks are the property of their respective owners. Inclusion in this market map is for informational and educational purposes only and does not imply any partnership, endorsement, or affiliation with GrowthVybz.
The information provided is based on publicly available sources (such as company websites, press releases, and industry reports) and is believed to be accurate at the time of publication. GrowthVybz makes no representations or warranties regarding completeness or accuracy, and accepts no liability for any errors or omissions.
This market map is an independent analysis created by GrowthVybz. It is not intended as investment advice or solicitation. Companies listed here are welcome to contact us to update or correct their information.
Note: GrowthVybz offers separate marketing, fundraising, and growth services. These services are independent offerings and are not endorsed or sponsored by the companies featured in this map.
